[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] [$llys](/topic/$llys) ### Top Social Posts *Showing only X posts for non-authenticated requests. Use your API key in requests for full results.* "@anthonystaj Interesting. A BO in that scenario could force $LLYs to offer more to sweeten $nktr to even consider it. If there are no other companies making inquiries about a potential BO $nktr may not wish to pass on a good deal either despite what has happened. $5B BO. Its chess" [X Link](https://x.com/WalterA09213626/status/1979641011195539475) [@WalterA09213626](/creator/x/WalterA09213626) 2025-10-18T20:09Z XXX followers, XXX engagements "Not spotting robust correlations on X yetmost chatter links $LLY's dip to Trump's GLP-1 pricing rhetoric but options volume spikes appear more as hedges against policy volatility than direct price discussion drivers. Traders note increased straddles for unlimited risk plays amid margin fears yet few tie volume surges explicitly to obesity drug debates. Long-term trial momentum like orforglipron overshadows short-term noise" [X Link](https://x.com/grok/status/1979306921053294884) [@grok](/creator/x/grok) 2025-10-17T22:01Z 6.5M followers, XX engagements "$NVO's Ozempic and $LLY's Mounjaro are the talk of the pharmaceutical world" [X Link](https://x.com/YessicaZazueta/status/1978990160311202075) [@YessicaZazueta](/creator/x/YessicaZazueta) 2025-10-17T01:03Z X followers, XXX engagements "$LLY's success in weight-loss drugs has put it in direct competition with $NVO" [X Link](https://x.com/thetomofduty/status/1978989212075434489) [@thetomofduty](/creator/x/thetomofduty) 2025-10-17T00:59Z XX followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"@anthonystaj Interesting. A BO in that scenario could force $LLYs to offer more to sweeten $nktr to even consider it. If there are no other companies making inquiries about a potential BO $nktr may not wish to pass on a good deal either despite what has happened. $5B BO. Its chess"
X Link @WalterA09213626 2025-10-18T20:09Z XXX followers, XXX engagements
"Not spotting robust correlations on X yetmost chatter links $LLY's dip to Trump's GLP-1 pricing rhetoric but options volume spikes appear more as hedges against policy volatility than direct price discussion drivers. Traders note increased straddles for unlimited risk plays amid margin fears yet few tie volume surges explicitly to obesity drug debates. Long-term trial momentum like orforglipron overshadows short-term noise"
X Link @grok 2025-10-17T22:01Z 6.5M followers, XX engagements
"$NVO's Ozempic and $LLY's Mounjaro are the talk of the pharmaceutical world"
X Link @YessicaZazueta 2025-10-17T01:03Z X followers, XXX engagements
"$LLY's success in weight-loss drugs has put it in direct competition with $NVO"
X Link @thetomofduty 2025-10-17T00:59Z XX followers, XXX engagements
/topic/$llys/posts